TipRanks
Advertisement
Advertisement

DE:84C0 Stock Latest News

Clene announces insider-led $4 million financing round
Company AnnouncementsClene announces insider-led $4 million financing round
21d ago
8K
CLNN
Clene prices 1.22M shares at $3.28 in registered direct offering
PremiumThe Fly
Clene prices 1.22M shares at $3.28 in registered direct offering
22d ago
CLNN
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval
PremiumTipRanks Newswire
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval
1M ago
CLNN
NRSN
Clene reports Q2 EPS ($1.08), consensus (26c)
PremiumThe Fly
Clene reports Q2 EPS ($1.08), consensus (26c)
2M ago
CLNN
CLNN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CLNN Upcoming Earnings Report: What to Expect?
2M ago
CLNN
Buy Rating Reaffirmed on CNM-Au8 ALS Progress, Regulatory Momentum; $31 Price Target Maintained
PremiumRatingsBuy Rating Reaffirmed on CNM-Au8 ALS Progress, Regulatory Momentum; $31 Price Target Maintained
2M ago
CLNN
Clene Advances ALS Program with Biomarker NDA Update
Premium
Company Announcements
Clene Advances ALS Program with Biomarker NDA Update
2M ago
8K
CLNN
Fourteen new option listings and one option delisting on July 22nd
Premium
The Fly
Fourteen new option listings and one option delisting on July 22nd
3M ago
ACOG
ARTV
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
PremiumTipRanks Newswire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
4M ago
SNY
BIIB
Clene Extends Note Maturities and Expands Equity Plan
PremiumCompany Announcements
Clene Extends Note Maturities and Expands Equity Plan
5M ago
8K
CLNN
Roth says FDA approving Clene’s ALS treatment NDA a ‘long shot’
PremiumThe Fly
Roth says FDA approving Clene’s ALS treatment NDA a ‘long shot’
5M ago
CLNN
Analyst Reiterates Buy on Advancing CNM-Au8 ALS Pathway and Funding Visibility; $31 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on Advancing CNM-Au8 ALS Pathway and Funding Visibility; $31 Price Target Maintained
5M ago
CLNN
Clene reports Q1 EPS (69c), consensus (70c)
PremiumThe FlyClene reports Q1 EPS (69c), consensus (70c)
5M ago
CLNN
Clene Extends Debt Maturities and Strengthens Cash Runway
Premium
Company Announcements
Clene Extends Debt Maturities and Strengthens Cash Runway
5M ago
8K
CLNN
CLNN Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
CLNN Earnings this Week: How Will it Perform?
5M ago
CLNN
Clene price target raised to $50 from $48 at Canaccord
PremiumThe Fly
Clene price target raised to $50 from $48 at Canaccord
5M ago
CLNN
Clene Announces $7 Million Registered Direct Equity Offering
PremiumCompany Announcements
Clene Announces $7 Million Registered Direct Equity Offering
5M ago
8K
CLNN
Clene provides update on NDA for ALS following Type C meeting with FDA
PremiumThe Fly
Clene provides update on NDA for ALS following Type C meeting with FDA
5M ago
CLNN
Clene Advances CNM-Au8 Toward Accelerated ALS Approval
PremiumCompany Announcements
Clene Advances CNM-Au8 Toward Accelerated ALS Approval
5M ago
8K
CLNN
Clene Secures Third-Year NIH Subaward for ALS Program
PremiumCompany AnnouncementsClene Secures Third-Year NIH Subaward for ALS Program
7M ago
8K
CLNN
Clene reports FY25 EPS ($2.65), consensus ($2.35)
Premium
The Fly
Clene reports FY25 EPS ($2.65), consensus ($2.35)
7M ago
CLNN
Clene outlines 2026 regulatory milestones and ALS strategy
Premium
Company Announcements
Clene outlines 2026 regulatory milestones and ALS strategy
8M ago
8K
CLNN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >